Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07CNY
|
||||
| Former ID |
DIB016518
|
||||
| Drug Name |
Instiladrin
|
||||
| Indication | Bladder cancer [ICD9: 188; ICD10:C67] | Phase 2 | [524056] | ||
| Company |
Fkd therapies
|
||||
| Target and Pathway | |||||
| Target(s) | Interferon alpha 2 ligand | Target Info | Modulator | [524056] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Regulation of autophagy | |||||
| PI3K-Akt signaling pathway | |||||
| Toll-like receptor signaling pathway | |||||
| RIG-I-like receptor signaling pathway | |||||
| Cytosolic DNA-sensing pathway | |||||
| Jak-STAT signaling pathway | |||||
| Natural killer cell mediated cytotoxicity | |||||
| Tuberculosis | |||||
| Hepatitis C | |||||
| Hepatitis B | |||||
| Measles | |||||
| Influenza A | |||||
| Herpes simplex infection | |||||
| Autoimmune thyroid disease | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Downstream signaling in naï | ||||
| References | |||||